# Colchicine and Post-COVID-19 Pulmonary Fibrosis

> **NCT04818489** · PHASE4 · UNKNOWN · sponsor: **ClinAmygate** · enrollment: 260 (actual)

## Conditions studied

- Covid19
- Pulmonary Fibrosis Interstitial

## Interventions

- **DRUG:** Colchicine 0.5 MG
- **OTHER:** the standard protocol only

## Key facts

- **NCT ID:** NCT04818489
- **Lead sponsor:** ClinAmygate
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-25
- **Primary completion:** 2021-08-25
- **Final completion:** 2023-10-20
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2023-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04818489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04818489, "Colchicine and Post-COVID-19 Pulmonary Fibrosis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04818489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*